HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of disseminated facial warts through contact immunotherapy with diphenylcyclopropenone (DPCP).

Abstract
This paper highlights the effect of diphenylcyclopropenone (DPCP) sensitization on warts resistant to other treatments and is interesting in views of the fact that all the facial warts apparently responded. To analyze the efficacy and side-effects of DPCP treatment of viral warts, a prospective study was designed to follow six patients with chronic and resistant facial warts through immunotherapy sensitization with diphenylcyclopropenone for 10 weekly sessions. Patients were first sensitized with 2 percent DPCP and then followed by weekly maintenance of 0.001-1 percent DPCP in acetone on facial warts until mild contact dermatitis was obtained. After application of DPCP to the warts of the face, all of the facial warts became inflamed and resolved. DPCP appears to be a valuable, safe, and well-tolerated treatment for resistant and chronic facial warts.
AuthorsShahin Aghaei
JournalDermatology online journal (Dermatol Online J) Vol. 12 Issue 2 Pg. 10 (Feb 28 2006) ISSN: 1087-2108 [Electronic] United States
PMID16638403 (Publication Type: Journal Article)
Chemical References
  • Cyclopropanes
  • Dermatologic Agents
  • diphenylcyclopropenone
Topics
  • Administration, Cutaneous
  • Adolescent
  • Cyclopropanes (therapeutic use)
  • Dermatologic Agents (therapeutic use)
  • Facial Dermatoses (therapy)
  • Female
  • Humans
  • Immunotherapy
  • Male
  • Treatment Outcome
  • Warts (therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: